{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:59:36Z","timestamp":1781632776099,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/IBSRF\/23\/25161, RE\/24\/130012"],"award-info":[{"award-number":["FS\/IBSRF\/23\/25161, RE\/24\/130012"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CH\/F\/21\/90010, RG\/20\/10\/34966, RE\/24\/130012"],"award-info":[{"award-number":["CH\/F\/21\/90010, RG\/20\/10\/34966, RE\/24\/130012"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W006804\/1"],"award-info":[{"award-number":["MR\/W006804\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Following myocardial infarction (MI), therapies are recommended that reduce risk and prevent future cardiovascular events. Trends in the provision of guideline-directed medical therapies by sex, age, ethnicity and socioeconomic deprivation status may help identify opportunities to reduce inequalities in post-MI care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cohort study using linked routine healthcare data included patients with MI in South-East Scotland (1 April 2009 to 31st of July 2021). Multivariable logistic regression models with a generalized estimating equation approach were used to assess the association between each sociodemographic factor and the provision of three guideline-directed medical therapies (anti-platelet or anti-thrombotic agent, lipid-lowering therapy and renin-angiotensin system blocker) at 3-, 12-, and 18-months post-discharge. Multivariable cause-specific Cox proportional hazard models were used to evaluate medication status and risk of a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death across sociodemographic subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population comprised 7,926 patients (35% female, mean age 65 [SD 13] years). At 3 months, 5,393 (68%) patients were receiving all three guideline-directed medical therapies. Women (adjusted odds ratio at 3 months [aOR 0.69, 95% confidence interval 0.62 to 0.77]) and patients\u2009&lt;\u200950 years (aOR 0.77, 95% confidence interval 0.65 to 0.89) and\u2009&gt;\u200970 years (aOR 0.58, 95% confidence interval 0.51 to 0.65) were less likely to be receiving all three guideline-directed medical therapies at 3 months with similar observations at 12 and 18 months. No differences were observed by ethnicity and socioeconomic groups across the three time points. Patients receiving all three or one\/two guideline-directed medical therapies had a lower risk of future cardiovascular events compared to those not receiving any, with this effect being consistent across all subgroups and time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women, and both younger and older patients are less likely to be receiving guideline-directed medical therapy following MI, despite its benefit in reducing future cardiovascular events. Targeted strategies to increase provision of secondary prevention in these groups are needed to reduce inequalities and improve post-MI care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05572-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:25:43Z","timestamp":1770373543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inequalities in the provision of guideline-directed medical therapy following myocardial infarction: a cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Fiona","family":"McLachlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"de Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesario","family":"Pancinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Caparrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulani","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Miller-Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Dhaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Tuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien M","family":"Kimenai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"19","key":"5572_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163\u201370.","journal-title":"Eur Heart J"},{"issue":"6","key":"5572_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2022.0662","volume":"7","author":"Y Wang","year":"2022","unstructured":"Wang Y, Leifheit EC, Krumholz HM. Trends in 10-year outcomes among Medicare beneficiaries who survived an acute myocardial infarction. JAMA Cardiol. 2022;7(6):613\u201322.","journal-title":"JAMA Cardiol"},{"issue":"34","key":"5572_CR3","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"5572_CR4","doi-asserted-by":"publisher","unstructured":"Pana TA, Mamas MA, Myint PK, Dawson DK. Sex differences in myocardial infarction care and outcomes: a longitudinal Scottish National Data-Linkage Study. Eur J Prev Cardiol. 2025;32(8):696\u2013707. https:\/\/doi.org\/10.1093\/eurjpc\/zwae333.","DOI":"10.1093\/eurjpc\/zwae333"},{"issue":"5","key":"5572_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/heartjnl-2022-321452","volume":"109","author":"I Thalmann","year":"2023","unstructured":"Thalmann I, Preiss D, Schlackow I, Gray A, Mihaylova B. Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009\u20132017. Heart. 2023;109(5):388\u201395.","journal-title":"Heart"},{"key":"5572_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2022.05.015","volume":"252","author":"AMK Minhas","year":"2022","unstructured":"Minhas AMK, Ijaz SH, Javed N, et al. National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: insights from National Ambulatory Medical Care Survey. Am Heart J. 2022;252:60\u20139.","journal-title":"Am Heart J"},{"issue":"8","key":"5572_CR7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.7326\/M23-0720","volume":"176","author":"DA Frank","year":"2023","unstructured":"Frank DA, Johnson AE, Hausmann LRM, Gellad WF, Roberts ET, Vajravelu RK. Disparities in guideline-recommended statin use for prevention of atherosclerotic cardiovascular disease by race, ethnicity, and gender\u202f: a nationally representative cross-sectional analysis of adults in the United States. Ann Intern Med. 2023;176(8):1057\u201366.","journal-title":"Ann Intern Med"},{"issue":"5","key":"5572_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155228","volume":"11","author":"H Zhang","year":"2016","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study. PLoS ONE. 2016;11(5):e0155228.","journal-title":"PLoS ONE"},{"issue":"4","key":"5572_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ehjqcco\/qcab007","volume":"8","author":"M Dagan","year":"2022","unstructured":"Dagan M, Dinh DT, Stehli J, et al. Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):420\u20138.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"4","key":"5572_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/2047487320912087","volume":"28","author":"G Mnatzaganian","year":"2021","unstructured":"Mnatzaganian G, Lee CMY, Robinson S, et al. Socioeconomic disparities in the management of coronary heart disease in 438 general practices in Australia. Eur J Prev Cardiol. 2021;28(4):400\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"5572_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1755-5922.12212","volume":"34","author":"AS Gunnell","year":"2016","unstructured":"Gunnell AS, Hung J, Knuiman MW, et al. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors. Cardiovasc Ther. 2016;34(6):423\u201330.","journal-title":"Cardiovasc Ther"},{"key":"5572_CR12","doi-asserted-by":"publisher","unstructured":"AlabasOA, Gale CP, Hall M, et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry. J Am Heart Assoc. 2017;6(12):e007123. https:\/\/doi.org\/10.1161\/JAHA.117.007123.","DOI":"10.1161\/JAHA.117.007123"},{"issue":"6","key":"5572_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.hlc.2021.11.014","volume":"31","author":"L Nedkoff","year":"2022","unstructured":"Nedkoff L, Lopez D, Hung J, et al. Validation of ICD-10-AM coding for myocardial infarction subtype in hospitalisation data. Heart Lung Circ. 2022;31(6):849\u201358.","journal-title":"Heart Lung Circ"},{"key":"5572_CR14","doi-asserted-by":"publisher","unstructured":"LowryMTH, Kimenai DM, Doudesis D, et al. The electronic frailty index and outcomes in patients with myocardial infarction. Age Ageing. 2024;53(7):afae150. https:\/\/doi.org\/10.1093\/ageing\/afae150.","DOI":"10.1093\/ageing\/afae150"},{"key":"5572_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100960","volume":"43","author":"M McDermott","year":"2024","unstructured":"McDermott M, Kimenai DM, Anand A, et al. Adoption of high-sensitivity cardiac troponin for risk stratification of patients with suspected myocardial infarction: a multicentre cohort study. Lancet Reg Health Eur. 2024;43:100960.","journal-title":"Lancet Reg Health Eur"},{"key":"5572_CR16","doi-asserted-by":"publisher","unstructured":"BoeddinghausJ, Li Z, Bularga A, et al. Clinical decisions and outcomes after switching high-sensitivity cardiac troponin assays in duspected ACS: an interrupted time-series study. JAMA Cardiol. 2025;e254661. https:\/\/doi.org\/10.1001\/jamacardio.2025.4661.","DOI":"10.1001\/jamacardio.2025.4661"},{"issue":"3","key":"5572_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/afw039","volume":"45","author":"A Clegg","year":"2016","unstructured":"Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353\u201360.","journal-title":"Age Ageing"},{"key":"5572_CR18","unstructured":"Government S. The Scottish Index of Multiple Deprivation. https:\/\/www.gov.scot\/collections\/scottish-index-of-multiple-deprivation-2020\/. Accessed 28 Jan 2025."},{"issue":"3","key":"5572_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.122.060042","volume":"146","author":"DM Kimenai","year":"2022","unstructured":"Kimenai DM, Pirondini L, Gregson J, et al. Socioeconomic deprivation: an important, largely unrecognized risk factor in primary prevention of cardiovascular disease. Circulation. 2022;146(3):240\u20138.","journal-title":"Circulation"},{"issue":"9798","key":"5572_CR20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","volume":"378","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231\u201343.","journal-title":"Lancet"},{"issue":"1","key":"5572_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.51156","volume":"6","author":"A Mufarreh","year":"2023","unstructured":"Mufarreh A, Shah AJ, Vaccarino V, Kulshreshtha A. Trends in provision of medications and lifestyle counseling in ambulatory settings by gender and race for patients with atherosclerotic cardiovascular disease, 2006\u20132016. JAMA Netw Open. 2023;6(1):e2251156.","journal-title":"JAMA Netw Open"},{"issue":"10292","key":"5572_CR22","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","volume":"397","author":"B Vogel","year":"2021","unstructured":"Vogel B, Acevedo M, Appelman Y, et al. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385\u2013438.","journal-title":"Lancet"},{"issue":"22","key":"5572_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-324625","volume":"110","author":"U Tayal","year":"2024","unstructured":"Tayal U, Pompei G, Wilkinson I, et al. Advancing the access to cardiovascular diagnosis and treatment among women with cardiovascular disease: a joint British Cardiovascular Societies\u2019 consensus document. Heart. 2024;110(22):e4.","journal-title":"Heart"},{"issue":"2","key":"5572_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead033","volume":"3","author":"M Lawless","year":"2023","unstructured":"Lawless M, Appelman Y, Beltrame JF, et al. Sex differences in treatment and outcomes amongst myocardial infarction patients presenting with and without obstructive coronary arteries: a prospective multicentre study. Eur Heart J Open. 2023;3(2):oead033.","journal-title":"Eur Heart J Open"},{"issue":"3","key":"5572_CR25","first-page":"163","volume":"3","author":"J Tamargo","year":"2017","unstructured":"Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J. 2017;3(3):163\u201382.","journal-title":"Eur Heart J"},{"issue":"7","key":"5572_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.119.043594","volume":"141","author":"X Jin","year":"2020","unstructured":"Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women\u2019s participation in cardiovascular clinical trials from 2010 to 2017. Circulation. 2020;141(7):540\u20138.","journal-title":"Circulation"},{"issue":"2","key":"5572_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ehjqcco\/qcad033","volume":"10","author":"C Qu","year":"2024","unstructured":"Qu C, Liao S, Zhang J, et al. Burden of cardiovascular disease among elderly: based on the Global Burden of Disease Study 2019. Eur Heart J Qual Care Clin Outcomes. 2024;10(2):143\u201353.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"15","key":"5572_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/CIRCULATIONAHA.122.059994","volume":"146","author":"MTH Lowry","year":"2022","unstructured":"Lowry MTH, Doudesis D, Wereski R, et al. Influence of age on the diagnosis of myocardial infarction. Circulation. 2022;146(15):1135\u201348.","journal-title":"Circulation"},{"issue":"11","key":"5572_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25505","volume":"3","author":"X Yao","year":"2020","unstructured":"Yao X, Shah ND, Gersh BJ, Lopez-Jimenez F, Noseworthy PA. Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016. JAMA Netw Open. 2020;3(11):e2025505-e.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"5572_CR30","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1007\/s40615-024-02195-7","volume":"12","author":"TM White","year":"2025","unstructured":"White TM, Borrell LN, El-Mohandes A. A review of the public health literature examining the roles of socioeconomic status and race\/ethnicity on health outcomes in the United States. J Racial Ethn Health Disparities. 2025;12(6):3991\u20134012.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"6","key":"5572_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/CIRCOUTCOMES.111.961193","volume":"4","author":"N Danchin","year":"2011","unstructured":"Danchin N, Neumann A, Tuppin P, et al. Impact of free universal medical coverage on medical care and outcomes in low-income patients hospitalized for acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2011;4(6):619\u201325.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"14","key":"5572_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/heartjnl-2024-325638","volume":"111","author":"M de Bakker","year":"2025","unstructured":"de Bakker M, Kimenai DM. Identifying determinants of cardiovascular medication non-adherence to develop individualised interventions. Heart. 2025;111(14):649\u201350.","journal-title":"Heart"},{"issue":"10","key":"5572_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/heartjnl-2024-325144","volume":"111","author":"R Kha","year":"2025","unstructured":"Kha R, Min H, Marschner S, et al. Determinants of medication adherence in patients with acute coronary syndrome: a secondary analysis of a randomised clinical trial. Heart. 2025;111(10):462\u201370.","journal-title":"Heart"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05572-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05572-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05572-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:39:49Z","timestamp":1781631589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05572-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5572"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05572-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Creation of and access to the linked data was approved by the local ethical review committee, with acknowledgement by The University of Edinburgh Usher Research Ethics Group team (UMREG ID: UM24106). The linked dataset was stored, accessed, prepared and analysed in the Electronic Data Research and Innovation Service save haven environment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DMK has received honoraria from Roche Diagnostics and Abbott Diagnostics. NLM has consulted for Abbott Diagnostics, Roche Diagnostics, and Siemens Healthineers. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}